- Home
- ZVIA vs VIGL Comparison
ZVIA vs VIGL Comparison
Compare ZVIA & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVIA
- VIGL
- Stock Information
- Founded
- ZVIA 2007
- VIGL 2020
- Country
- ZVIA United States
- VIGL United States
- Employees
- ZVIA N/A
- VIGL N/A
- Industry
- ZVIA Beverages (Production/Distribution)
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ZVIA Consumer Staples
- VIGL Health Care
- Exchange
- ZVIA Nasdaq
- VIGL Nasdaq
- Market Cap
- ZVIA 116.8M
- VIGL 95.2M
- IPO Year
- ZVIA 2021
- VIGL 2022
- Fundamental
- Price
- ZVIA $3.81
- VIGL $1.66
- Analyst Decision
- ZVIA Hold
- VIGL Strong Buy
- Analyst Count
- ZVIA 4
- VIGL 5
- Target Price
- ZVIA $1.56
- VIGL $19.75
- AVG Volume (30 Days)
- ZVIA 823.2K
- VIGL 353.8K
- Earning Date
- ZVIA 02-25-2025
- VIGL 11-07-2024
- Dividend Yield
- ZVIA N/A
- VIGL N/A
- EPS Growth
- ZVIA N/A
- VIGL N/A
- EPS
- ZVIA N/A
- VIGL N/A
- Revenue
- ZVIA $153,385,000.00
- VIGL N/A
- Revenue This Year
- ZVIA N/A
- VIGL N/A
- Revenue Next Year
- ZVIA $7.64
- VIGL N/A
- P/E Ratio
- ZVIA N/A
- VIGL N/A
- Revenue Growth
- ZVIA N/A
- VIGL N/A
- 52 Week Low
- ZVIA $0.62
- VIGL $1.54
- 52 Week High
- ZVIA $3.98
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- ZVIA 74.07
- VIGL 26.02
- Support Level
- ZVIA $2.98
- VIGL $1.54
- Resistance Level
- ZVIA $3.30
- VIGL $1.89
- Average True Range (ATR)
- ZVIA 0.35
- VIGL 0.16
- MACD
- ZVIA 0.00
- VIGL -0.00
- Stochastic Oscillator
- ZVIA 87.34
- VIGL 13.19
About ZVIA Zevia PBC
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.